Personalized immune cells take aim at tough liver cancers
NCT ID NCT06968195
Summary
This early-stage study is testing a new treatment for advanced liver cancer that has come back or stopped responding to standard therapies. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose and see if this approach is tolerable for people with this difficult-to-treat cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.